Thumbnail Image

Birsa Agricultural University, Ranchi

Browse

20102
Reset filters
Author: Rupam, Richa × End date: 2019 × Start date: 2010 × Thesis Type: M.V.Sc. ×
Reset filters

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    ThesisItemOpen Access
    Pharmacokinetic Studies Of Levofloxacin In Healthy And Hepatopathic Turkeys
    (Birsa Agricultural University, Kanke, Ranchi, Jharkhand, 2010) Rupam, Richa; Roy, B. K.
     An overall view of result obtained indicated that LVX persisted for longer time in hepatopathic turkeys in case of both i.v. and oral administrations.  Based on pharmacokinetic parameters LVX may be given i.v. @5.09 mg/kg body weight at 66.13h interval and orally @12.49mg/kg body weight at 88.16h interval in hepatopathic turkeys.
  • Thumbnail Image
    ThesisItemOpen Access
    Pharmacokinetic Studies Of Levofloxacin In Healthy And Hepatopathic Turkeys
    (Birsa Agricultural University, Kanke, Ranchi, Jharkhand, 2010) Rupam, Richa; Roy, B. K.
    The pharmacokinetic studies of levofloxacin (LVX) after intravenous (10 mg/kg body weight) and oral (20 mg/kg body weight) administration were conducted in healthy and hepatopathic turkeys. The silent features of the findings are given below: Intravenous administration: 1) The tCpther observed in hepatopathic turkeys (36 h) was longer than healthy (12 h). 2) The mean β value of LVX observed in hepatopathic turkeys (0.08±0.00 h–1) was significantly (p<0.01) lower as compared to healthy turkeys (0.26±0.01 h-1). 3) The mean t1/2β of LVX observed in hepatopathic turkeys (8.15±0.44 h) was significantly (p<0.01) longer as compared to healthy turkeys (2.68±0.14 h). 4) The mean AUC value of LVX in hepatopathic turkeys (50.63±6.70mg/L.h) was significantly (p<0.01) increased than healthy turkeys (21.39±1.99 mg/L.h). 5) The mean AUMC value of LVX in hepatopathic turkeys (570.32±156.53mg/L.h) was significantly (p<0.05) increased than healthy turkeys (80.80±11.40 mg/L.h). Pharmacokinetic studies of levofloxacin in healthy & hepatopathic turkeys 6) The MRT of LVX was significantly (p<0.01) longer in hepatopathic turkeys (12.38±0.78 h) to that observed in healthy turkeys (3.68±0.23 h). 7) The mean ClB value of LVX was found to be significantly (p<0.01) lower in hepatopathic turkeys (3.66±0.47 ml/kg/min) as compared to healthy turkeys (8.37±1.06 ml/kg/min). 8) The mean k21 value of LVX was found to be significantly (p<0.05) lower in hepatopathic turkeys (1.95±0.19 h–1) as compared to healthy turkeys (2.90±0.27 h–1). 9) The mean value of T/P ratio of LVX in hepatopathic turkeys (1.71±0.14) was significantly (p<0.05) higher as compared to healthy turkeys (1.16±0.15). Oral administration: 1) The mean Cpmax of LVX in hepatopathic turkeys (5.95±0.29 μg/ml) was non significantly increased as compared to healthy turkeys (5.34±0.26 μg/ml) and attained Tmax at 2 h in both cases. 2) The tCpther observed in healthy and hepatopathic turkeys were 24 h and 48 h respectively. Pharmacokinetic studies of levofloxacin in healthy & hepatopathic turkeys 3) The mean t1/2β of LVX was significantly (p<0.01) longer in hepatopathic turkeys (11.69±0.24 h) as compared to healthy (6.94±0.21 h). 4) The mean AUMC value of hepatopathic turkeys (957.85±64.20 mg/L.h) was significantly (p<0.01) higher than healthy turkeys (435.10±51.52 mg/L.h). 5) The MRT of LVX was found to be significantly (p<0.01) longer in hepatopathic turkeys (17.47±0.46 h) as compared to healthy turkeys (10.41±0.40 h). 6) The mean ClB value of LVX in hepatopathic turkeys (6.20±0.34 ml/kg/min) was significantly (p<0.01) decreased as compared to healthy turkeys (8.34±0.55 ml/kg/min). 7) The mean Vdarea of LVX in hepatopathic turkeys (6.28±0.38 L/kg) was significantly (p<0.05) increased as compared to healthy turkeys (4.97±0.27 L/kg). CONCLUSION  An overallview of result obtained indicated that LVX persisted for longer time in hepatopathic turkeys in case of both i.v. and oral administrations.  Based on pharmacokinetic parameters LVX may be given i.v. @5.09 mg/kg body weight at 66.13h interval and orally @12.49mg/kg body weight at 88.16h interval in hepatopathic turkeys.